Adding a new medicine to shorter treatment for drug-resistant TB
Part of Infections clinical trials.
This study tests whether adding a medicine called acetohydroxamic acid to a shorter TB treatment is safe and effective for people with drug-resistant TB. If you have rifampicin-resistant TB, this might offer a simpler, shorter treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 14 and 65 years old.
- You need to have TB that is resistant to rifampicin (drug-resistant TB).
- Your TB must be in your lungs or in a body site other than the brain, bones, or widespread infection.
- You must weigh at least 40 kg (about 88 pounds).
- You need to be in reasonably good overall health (Karnofsky score of 50 or higher).
- Your blood counts, liver, and kidney function must be within acceptable ranges.
- You must test negative for HIV.
- You must not have taken bedaquiline, delamanid, or linezolid for more than one month before.
- Females who can become pregnant must use effective birth control and have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.
This study tests a shorter six-month treatment for tuberculosis that is resistant to rifampicin, a common antibiotic. The goal is to make treatment easier and possibly safer while still being effective.
This study tests a new combination of two existing medicines (pyrazinamide and hydroxychloroquine) to see if it works as well as the current standard treatment for TB. If it works, it could mean fewer pills or a shorter treatment for patients with drug-sensitive TB.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
This trial tests whether a shorter treatment using the drug rifampicin is as good as the usual longer treatment for people with less severe tuberculosis (TB). If you join, you'd get a shorter course of pills, which might be more convenient and have fewer side effects.
Hear when a new Rifampicin-resistant Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.